Intravenous magnesium sulfate for acute wheezing in young children: a randomised double-blind trial.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

Inclusion criteria were severe wheezing, classified as a score of ≥6 points as assessed by the Respiratory Distress Assessment Instrument (RDAI) after initial treatment with salbutamol, and the symptoms of acute viral infection.

Who Took Part

The abstract describes 61 children taking part.

By PubMed's age tags, the people studied were infants and young children, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

The children were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.

What Was Measured

Inclusion criteria were severe wheezing, classified as a score of ≥6 points as assessed by the Respiratory Distress Assessment Instrument (RDAI) after initial treatment with salbutamol, and the symptoms of acute viral infection.

Topics PubMed links to this paper include Acute Disease, Administration, Intravenous, Albuterol, Asthma, Bronchodilator Agents, Dyspnea and Finland.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 61 children.

The publication is from 2018 (The European respiratory journal), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.